Physician profile
Abdo Chafic Kataya
NPI 1851598478
$15,653.01
in general payments reported to CMS, 2019-2025
34 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $160 · 2021: $438 · 2022: $778 · 2023: $4,587 · 2024: $6,562 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $11K · Food and Beverage: $2,011 · Travel and Lodging: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,596.37 |
| Food and Beverage | $2,010.78 |
| Travel and Lodging | $811.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,427.28 | 2023-2025 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $580.26 | 2020-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.83 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $418.94 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $315.24 | 2021-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $184.58 | 2019-2025 | Winrevair, Keytruda |
| Inari Medical, INC. | $158.50 | 2019 | |
| Inspire Medical Systems, INC. | $154.94 | 2023-2025 | Inspire |
| Genzyme Corporation | $153.18 | 2021-2024 | |
| United Therapeutics Corporation | $146.62 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $134.06 | 2022-2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $130.30 | 2021-2023 | |
| Genentech USA, INC. | $124.77 | 2019 | |
| Pfizer INC. | $123.72 | 2019 | |
| Electromed, INC. | $118.31 | 2021-2025 | Smartvest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $101.58 | 2021-2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $97.67 | 2022-2023 | Xarelto |
| Insmed, INC. | $97.04 | 2023-2025 | Brinsupri, Arikayce |
| Mallinckrodt Hospital Products INC. | $84.37 | 2021-2023 | Acthar |
| Baxter Healthcare | $80.64 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Astellas Pharma US INC | $76.99 | 2019 | |
| Amgen INC. | $67.24 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $56.45 | 2021-2022 | |
| Abbvie INC. | $44.66 | 2021-2023 | |
| Ambu INC. | $39.79 | 2024-2025 | |
| Philips North America LLC | $36.41 | 2024 | (Ae4) Secretion Management |
| Teva Pharmaceuticals USA, INC. | $29.72 | 2022 | |
| Pulmonx Corporation | $25.29 | 2022 | |
| Advanced Respiratory, INC | $24.59 | 2021 | |
| Grifols USA, LLC | $22.85 | 2024 | Prolastin-C Liquid |
| Ethicon INC. | $22.60 | 2022 | |
| Vapotherm INC | $19.15 | 2022 | |
| Gilead Sciences, INC. | $17.80 | 2022 | |
| Tactile Systems Technology INC | $14.64 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdo Kataya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.